Can I Take Ashwagandha with Belsomra (Suvorexant)?

What Is Suvorexant and How Does It Work?

Suvorexant (Belsomra) is an FDA-approved dual orexin receptor antagonist (DORA) indicated for adults with insomnia characterized by difficulty with sleep onset or maintenance. The FDA approved it in August 2014 at doses of 5 mg to 20 mg taken no more than once per night, within 30 minutes of bedtime. [1]

Orexin Pathway Basics

Orexin A and orexin B are neuropeptides produced in the lateral hypothalamus. They bind OX1R and OX2R receptors to promote wakefulness, appetite, and arousal. Suvorexant competitively blocks both receptor subtypes, effectively "switching off" the wake-drive rather than non-specifically sedating the brain. This is the mechanistic distinction that separates DORAs from benzodiazepines and Z-drugs. [2]

CYP3A4 Metabolism

Suvorexant is metabolized primarily by CYP3A4 in the liver. The FDA label explicitly states that strong CYP3A4 inhibitors (for example, ketoconazole) can increase suvorexant exposure by roughly 2-fold, and that the dose should not exceed 10 mg when a moderate CYP3A4 inhibitor is co-administered. [1] This metabolic route is directly relevant to ashwagandha, as discussed below.

What Is Ashwagandha and Why Do People Stack It with Sleep Aids?

Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen used for stress reduction, cortisol modulation, and sleep quality improvement. Two standardized commercial extracts dominate the clinical literature: KSM-66 (5% withanolide glycosides) and Sensoril (10% withanolides). Doses studied in randomized controlled trials range from 240 mg to 600 mg per day, typically in one or two divided doses. [3]

Sleep-Specific Evidence

A randomized, double-blind, placebo-controlled trial (N=150) published in PLOS ONE found that KSM-66 ashwagandha 120 mg/day for six weeks significantly improved sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI) versus placebo (P<0.05). [4] A separate crossover trial (N=80) using Sensoril 300 mg twice daily for eight weeks reported a 72% improvement in sleep quality scores versus 29% for placebo. [5] These documented sleep-promoting effects are precisely why patients already on Belsomra sometimes ask about adding ashwagandha, either for stress or to "boost" sleep quality.

Cortisol Reduction

A 60-day, double-blind RCT (N=64) published in the Indian Journal of Psychological Medicine showed ashwagandha root extract 300 mg twice daily reduced serum cortisol by 27.9% compared to 7.9% in the placebo group (P<0.0001). [6] Cortisol is physiologically stimulating at night; reducing it can lower the arousal threshold, which is additive to what suvorexant does via orexin blockade.

The Two Core Interaction Mechanisms

Mechanism 1: CYP3A4 Pharmacokinetic Interaction

Suvorexant's FDA label is unambiguous: CYP3A4 inhibition raises suvorexant blood levels. [1] In vitro and early-phase pharmacology data suggest ashwagandha withanolides inhibit CYP3A4 activity. A 2019 in vitro study published in Drug Metabolism and Disposition demonstrated that Withania somnifera extracts meaningfully inhibited CYP3A4-mediated testosterone 6-beta-hydroxylation (IC50 values in the low micromolar range). [7] In vivo human data on this specific interaction with suvorexant do not yet exist, but the mechanistic basis for concern is established.

If CYP3A4 activity is reduced by ashwagandha, suvorexant clearance slows. Higher-than-expected suvorexant plasma concentrations increase the risk of next-day sedation, cognitive impairment, and CNS depression.

Mechanism 2: Additive Pharmacodynamic Sedation

Both agents independently produce CNS sedation. The concern is not that they share a receptor; it is that they suppress wakefulness through parallel pathways.

Suvorexant reduces orexin-driven arousal. Ashwagandha's triethylene glycol (TEG) constituent, identified in a mouse model study in PLOS ONE, appears to induce sleep through a non-orexin pathway, potentially involving GABA-A receptor modulation. [8] Two sedating agents acting on separate pathways can still produce additive, or occasionally supra-additive, CNS depression. This is the same principle that makes combining alcohol with antihistamines dangerous even though they use different mechanisms.

The HealthRX Interaction Risk Framework for ashwagandha plus suvorexant uses three tiers. Tier 1 (low risk): ashwagandha dose <300 mg/day, standardized to <5% withanolides, taken in the morning, no history of excessive sedation on suvorexant alone. Tier 2 (moderate risk): ashwagandha 300 to 600 mg/day, any withanolide standardization, taken within four hours of suvorexant dosing. Tier 3 (higher risk): ashwagandha above 600 mg/day, dose taken concurrently with suvorexant, plus any other CNS depressant in the regimen. Tier 2 and Tier 3 require a prescriber conversation before initiating.

Cortisol, Orexin, and the Hypothalamic Sleep-Wake Axis

Orexin neurons in the lateral hypothalamus do not operate in isolation. They receive input from the HPA axis, meaning cortisol and CRH influence orexin tone. [9] Ashwagandha's well-documented cortisol-lowering effect therefore touches the same regulatory network that suvorexant targets, though one level upstream.

A 2021 systematic review and meta-analysis (N=1,068 across 12 RCTs) published in Medicine concluded that ashwagandha supplementation significantly reduced perceived stress and cortisol versus placebo (standardized mean difference for cortisol: -0.55, 95% CI -0.84 to -0.26, P<0.0001). [10] Whether this upstream effect meaningfully alters suvorexant's efficacy or duration of action has not been tested in a clinical trial. The interaction is theoretically plausible rather than proven, but it deserves mention because it could affect how long suvorexant keeps working through the night.

Thyroid Considerations

Ashwagandha raises thyroid hormone levels in clinical studies. A randomized controlled trial (N=50) published in the Journal of Alternative and Complementary Medicine found that ashwagandha root extract 600 mg/day for eight weeks significantly increased serum T3 and T4 versus placebo (P<0.05 for both). [11] Thyroid hormones are stimulating; elevated T3 can worsen insomnia, counteracting the therapeutic goal of suvorexant therapy.

Patients combining the two agents long-term should have TSH, free T3, and free T4 checked at baseline and again at three months. Any drift in thyroid function warrants a prescriber review of the supplement regimen.

Testosterone and Hormonal Context

Ashwagandha is popular in TRT-adjacent and men's health contexts because it raises luteinizing hormone (LH) and testosterone. A 2019 pilot RCT (N=43) published in Medicine reported that ashwagandha 675 mg/day for 90 days increased testosterone levels by 14.7% versus 2.5% in the placebo group (P<0.05). [12] Suvorexant does not meaningfully interact with the HPG axis, so testosterone elevation from ashwagandha is not a direct drug-drug interaction concern.

However, testosterone increases energy, libido, and early-morning arousal. At higher ashwagandha doses, testosterone-driven stimulation in the morning could work against the residual sleep-maintenance benefit some patients seek from suvorexant. This effect is speculative but worth noting in patients who report unexpected early awakening after starting ashwagandha.

Dose-Timing Strategies to Reduce Interaction Risk

Separating dosing by time does not eliminate a CYP3A4 pharmacokinetic interaction, because enzyme inhibition is not acutely reversible. CYP3A4 inhibition from ashwagandha persists as long as withanolide plasma levels remain elevated. However, separating the doses does reduce pharmacodynamic sedation overlap.

Practical guidance based on current pharmacology:

• Take ashwagandha in the morning, not at night, when using it alongside Belsomra.
• Use the lowest effective ashwagandha dose. Most clinical trials showing benefit used 300 to 600 mg/day. Starting at 300 mg/day is reasonable.
• Do not exceed suvorexant 10 mg if you are taking ashwagandha daily, consistent with the FDA's guidance on moderate CYP3A4 inhibitor co-administration. [1]
• Avoid adding other CNS depressants (alcohol, benzodiazepines, antihistamines, melatonin in high doses) to this combination without explicit prescriber approval.
• Report any next-day cognitive fog, difficulty driving, or unusual sedation to your prescriber promptly.

What the Guidelines and Databases Say

The Natural Medicines Comprehensive Database rates the ashwagandha-CNS-depressant interaction as "Moderate," meaning "use with caution and monitor." Their rationale cites the additive sedation mechanism and the possibility that ashwagandha may slow metabolism of sedative drugs. [13]

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guidelines for chronic insomnia treatment in adults endorse pharmacological therapy with evidence-based agents, and note that concurrent supplement use should be reviewed for interactions. [14] They do not specifically address ashwagandha-DORA combinations, which reflects the evidence gap rather than a green light.

The FDA Belsomra prescribing information states directly: "Avoid use with other CNS depressants. Caution is required when BELSOMRA is used in combination with other CNS depressants because of potentially additive effects." [1] Ashwagandha's sedative properties place it within the scope of that warning, even though it is not a scheduled substance.

Monitoring Parameters If You Are Already Taking Both

Some patients reading this article are already combining ashwagandha and suvorexant. Stopping abruptly is not automatically necessary, but a structured review is.

Labs to Consider

• TSH, free T3, free T4: check at baseline and 12 weeks if ashwagandha use continues
• Morning cortisol: optional but useful in patients with HPA-axis concerns
• No specific suvorexant blood level monitoring exists clinically, but excess sedation is the functional proxy

Symptom Monitoring

Ask yourself these questions at each week for the first four weeks:

1. Am I unusually drowsy the next morning?
2. Is it harder than expected to drive or concentrate before noon?
3. Am I sleeping more than nine hours without feeling refreshed?

Any "yes" warrants a call to your prescriber. Dose reduction of suvorexant to 5 mg may resolve the sedation overlap, or a morning-only ashwagandha protocol may help, but your physician should guide that change.

Drug Interaction Screening

A 2023 cross-sectional study in Nutrients (N=2,041 supplement users) found that 63.4% of adults taking prescription sleep medications were simultaneously using at least one supplement with a plausible interaction, and only 24% had disclosed that supplement use to their physician. [15] Disclosure matters. Your pharmacist can run a formal drug-supplement interaction screen in under five minutes.

Special Populations

Older Adults

Adults over 65 are at higher risk of fall-related injury from any sedating agent. The Beers Criteria 2023 update from the American Geriatrics Society cautions against routine use of sedative-hypnotic drugs in older adults, and specifically includes orexin antagonists in its review of sleep agents requiring caution. [16] Adding a sedating supplement to suvorexant in a patient over 65 raises fall risk meaningfully. This population should avoid the combination unless a geriatric specialist or sleep medicine physician has approved it.

Patients with Thyroid Disease

Patients with existing hypothyroidism or hyperthyroidism should avoid ashwagandha without endocrinologist sign-off, regardless of concurrent Belsomra use, given its documented effect on T3 and T4. [11]

Patients on CYP3A4-Sensitive Medications

If you take any other CYP3A4-sensitive drug, including certain statins, immunosuppressants, or calcium-channel blockers, the addition of ashwagandha as a potential CYP3A4 inhibitor deserves broader pharmacist review. [7]

A Direct Clinical Summary

Combining ashwagandha with suvorexant is not a hard contraindication. It is a combination that requires medical review before initiating, and active monitoring afterward. The interaction risk is moderate, not minimal. Two distinct mechanisms apply: slower suvorexant clearance via CYP3A4 inhibition and additive CNS sedation through parallel sleep-promoting pathways.

Patients who want to use ashwagandha for stress or sleep support alongside Belsomra should tell their prescriber the exact formulation, the dose, and the timing. Using ashwagandha 300 mg/day taken in the morning, with suvorexant capped at 10 mg at night, represents the lower-risk end of this combination based on current pharmacology.